Press Releases

News & Events

Keep up-to-date with BioLineRx's company announcements by visiting the press release archive.

Press Releases

Press Releases

Date Title and Summary
Toggle Summary08/06/19 BioLineRx Reports Second Quarter 2019 Financial Results and Provides Corporate Update
On track for Phase 2 data read-out in pancreatic cancer by year-end 2019 Management to hold conference call today, August 6, at 10:00 am EDT TEL AVIV, Israel , Aug. 6, 2019 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology,
Toggle Summary07/30/19 BioLineRx to Report Second Quarter 2019 Results on August 6, 2019
Management to hold conference call at 10:00 a.m. EDT TEL AVIV, Israel , July 30, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended
Toggle Summary06/28/19 BioLineRx Announces Change in Ratio of American Depositary Shares to Ordinary Shares
TEL AVIV, Israel , June 28, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary
Toggle Summary06/13/19 BioLineRx to Present at the JMP Securities 2019 Life Sciences Conference
TEL AVIV, Israel , June 13, 2019 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Chief Executive Officer, Philip Serlin , will present a company update at the JMP Securities 2019 Life Sciences
Toggle Summary05/14/19 BioLineRx Reports First Quarter 2019 Financial Results and Provides Corporate Update
On track for Phase 2 data read-outs in pancreatic cancer and consolidation AML by year-end 2019 Management to hold conference call today, May 14, at 10:00 am EDT TEL AVIV, Israel, May 14, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company
Toggle Summary05/07/19 BioLineRx to Report First Quarter 2019 Results on May 14, 2019
Management to hold a conference call at 10:00 a.m. EDT Tel Aviv, Israel, May 7, 2019 --- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended March 31, 2019 on
Toggle Summary05/07/19 BioLineRx Announces FDA Approval of IND Application for AGI-134, a Novel Immunotherapy Anti-Cancer Vaccine for Solid Tumors
- Phase 1/2a study ongoing in the UK and Israel, with sites in the US expected to join by H1 2020 - - Initial safety results expected in H2 2019; initial efficacy results expected by year-end 2020 - TEL AVIV, Israel, May 7, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a
Toggle Summary03/28/19 BioLineRx Reports Year End 2018 Financial Results and Provides Corporate Update
BL-8040 and AGI-134 oncology programs progressing, with multiple data read-outs expected in the next 12 months Management to hold conference call today, March 28, at 10:00 am EDT TEL AVIV, Israel, March 28, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage
Toggle Summary03/27/19 BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients
Results presented as oral presentation at 45th Annual Meeting of European Society for Blood and Marrow Transplantation TEL AVIV, Israel, March 27, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that
Toggle Summary03/21/19 BioLineRx to Report Annual 2018 Results on March 28, 2019
Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel, March 21, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its audited annual financial results for the year
Toggle Summary03/14/19 BioLineRx to Present at the 29th Annual Oppenheimer Healthcare Conference
TEL AVIV, Israel, March 14, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Chief Executive Officer, Philip Serlin, will present a company update at the 29th Annual Oppenheimer Healthcare
Toggle Summary02/07/19 BioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants
TEL AVIV ,   Israel , Feb. 7, 2019 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has closed its previously announced underwritten public offering of 28,000,000 American Depositary Shares
Toggle Summary02/05/19 BioLineRx Announces Pricing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants
TEL AVIV, Israel , Feb. 5, 2019 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has priced an underwritten public offering of 28,000,000 American Depositary Shares ("ADSs"), each representing
Toggle Summary02/04/19 BioLineRx Announces Proposed Underwritten Public Offering of its American Depositary Shares and Warrants
TEL AVIV, Israel , Feb. 4, 2019 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has commenced an underwritten public offering of American Depositary Shares ("ADSs"), each representing one of
Toggle Summary02/04/19 BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
TEL AVIV, Israel , Feb. 4, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that the U.S. Food and Drug Administration ( FDA ) has granted Orphan Drug Designation to its lead oncology candidate, BL-8040,
Toggle Summary01/02/19 BioLineRx to Present at the 2019 Biotech Showcase
TEL AVIV, Israel , January 2, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that management will provide a corporate update at the 2019 Biotech Showcase in San Francisco, California .
Toggle Summary12/11/18 BioLineRx Announces Initiation of Triple Combination Arm of Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer Under Immuno-Oncology Collaboration
Results of triple combination arm of BL-8040, KEYTRUDA® and chemotherapy expected in H2 2019 TEL AVIV, Israel , Dec. 11, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the initiation of
Toggle Summary12/06/18 BioLineRx to Host Investor and Analyst Breakfast Meeting on December 11, 2018 in New York
TEL AVIV, Israel , December 6, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will host an investor breakfast meeting on Tuesday, December 11, 2018 at the Convene Conference
Toggle Summary11/20/18 BioLineRx Announces Receipt of FDA Biological Product Designation for Novel Cancer Immunotherapy Candidate AGI-134
- Designation provides eligibility for 12 years of market exclusivity that complements robust IP estate - - Phase 1/2a study ongoing with topline data expected by year-end 2020 - TEL AVIV, Israel , Nov. 20, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage
Toggle Summary11/08/18 BioLineRx Reports Significant Progress Across Oncology Programs and Provides Third Quarter Financial Update
Management to hold conference call at 10:00 am EST TEL AVIV, Israel , Nov. 8, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the third quarter ended September 30,
Toggle Summary11/01/18 BioLineRx to Report Third Quarter 2018 Results on November 8, 2018
Management to hold conference call at 10:00 a.m. EST TEL AVIV, Israel , November 1, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will release its unaudited financial results for the
Toggle Summary10/20/18 BioLineRx Discloses Additional Data from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress
Results presented today demonstrate that BL-8040 significantly improves T-cell infiltration into the tumor and reduces immunosuppression in the tumor microenvironment TEL AVIV, Israel , October 20, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) (TASE: BLRX.TA), a clinical-stage
Toggle Summary10/19/18 BioLineRx Presents Top-line Results from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress
BL-8040 in combination with KEYTRUDA® (pembrolizumab) demonstrated encouraging disease control and overall survival in patients with metastatic pancreatic cancer Encouraging results support further development of combination and expansion of collaboration Triple combination expansion cohort
Toggle Summary10/03/18 BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications
Transaction increases BioLineRx's stake by 20%, to 80%, ahead of numerous potential value-creating milestones Top-line results from ongoing Phase 2a pancreatic cancer study in combination with KEYTRUDA® expected this quarter Management to hold conference call today, October 3, at 10:00 am EDT TEL
Toggle Summary08/30/18 BioLineRx to Present at 20th Annual Rodman & Renshaw Global Investment Conference in New York
TEL AVIV, Israel , August 30, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that its Chief Executive Officer, Philip Serlin , will present a company update at the 20th Annual Rodman &
Toggle Summary08/13/18 BioLineRx Reports Second Quarter 2018 Financial Results
TEL AVIV, Israel , Aug. 13, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the second quarter ended June 30, 2018 .
Toggle Summary08/07/18 BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization
Data from first lead-in patient cohort prompts Data Monitoring Committee to recommend early continuation to randomized placebo-controlled part 2 of trial TEL AVIV, Israel , August 7, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused
Toggle Summary08/06/18 BioLineRx to Report Second Quarter 2018 Results on August 13, 2018
Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , Aug. 6, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will release its unaudited financial results for the
Toggle Summary08/01/18 BioLineRx Initiates Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors
TEL AVIV , Israel , August 1, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it has initiated a Phase 1/2a clinical study for AGI-134, a novel compound that evokes a direct
Toggle Summary07/30/18 BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer
30-50 patients in additional arm will be investigated under the collaboration Results from combination of BL-8040 and KEYTRUDA® (pembrolizumab) in COMBAT/KEYNOTE-202 study will be reported in H2 2018 as planned TEL AVIV, Israel , July 30, 2018 /PRNewswire/ -- BioLineRx Ltd.
Toggle Summary06/18/18 BioLineRx Presents New Overall Survival Data From Phase 2a Study for BL-8040 in r/r AML Patients
Data presented at EHA shows significantly improved overall survival compared to historical data Potential biomarker identified for future patient selection, based on statistically significant correlation between responders and levels of AML blast mobilization to peripheral blood TEL AVIV, Israel ,
Toggle Summary06/13/18 BioLineRx to Participate at JMP Securities 2018 Life Sciences Conference
TEL AVIV, Israel , June 13, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief Executive Officer, Philip Serlin , will participate in a panel discussion at JMP Securities 2018
Toggle Summary06/13/18 BioLineRx to Participate at JMP Securities 2018 Life Sciences Conference
TEL AVIV, Israel , June 13, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief Executive Officer, Philip Serlin , will participate in a panel discussion at JMP Securities 2018
Toggle Summary05/22/18 BioLineRx Reports First Quarter 2018 Financial Results
TEL AVIV, Israel , May 22, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the first quarter ended March 31, 2018 .
Toggle Summary05/22/18 BioLineRx Reports First Quarter 2018 Financial Results
TEL AVIV, Israel , May 22, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the first quarter ended March 31, 2018 .
Toggle Summary05/17/18 BioLineRx to Present Overall Survival Data at EHA from Phase 2a Study of BL-8040 in r/r AML Patients
BL-8040 in combination with Cytarabine showed significantly improved overall survival compared to historical data TEL AVIV, Israel , May 17, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced
Toggle Summary05/17/18 BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation
- BL-8040 was safe and well tolerated, and all transplanted recipients were successfully engrafted - - Full top-line results will be presented at the 23rd EHA Congress - TEL AVIV, Israel , May 17, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical
Toggle Summary05/16/18 BioLineRx to Report First Quarter 2018 Results on May 22, 2018
Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , May 16, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX)( TASE: BLRX)( BLRX) , a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will release its unaudited financial results
Toggle Summary05/16/18 BioLineRx to Report First Quarter 2018 Results on May 22, 2018
Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , May 16, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX)( TASE: BLRX)( BLRX) , a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will release its unaudited financial results
Toggle Summary05/16/18 BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid Leukemia
Patent valid through March 2034, with up to five years' patent term extension TEL AVIV, Israel , May 16, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX)( BLRX) , a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that the European Patent
Toggle Summary03/26/18 BioLineRx Announces Notice of Allowance From USPTO for Patent Covering AGI-134 - a Novel Immunotherapy for Treating Solid Tumors
TEL AVIV, Israel , March 26, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a
Toggle Summary03/14/18 BioLineRx to Present at the 28th Annual Oppenheimer Healthcare Conference
TEL AVIV, Israel , March 14, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief Executive Officer, Philip Serlin , will present a company update at the 28 th Annual
Toggle Summary03/14/18 BioLineRx to Present at the 28th Annual Oppenheimer Healthcare Conference
TEL AVIV, Israel , March 14, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief Executive Officer, Philip Serlin , will present a company update at the 28 th Annual
Toggle Summary03/06/18 BioLineRx Reports Year End 2017 Financial Results
TEL AVIV, Israel , March 6, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the year ended December 31, 2017 . Highlights and achievements in 2017 and to date: Continued
Toggle Summary03/06/18 BioLineRx Reports Year End 2017 Financial Results
TEL AVIV, Israel , March 6, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the year ended December 31, 2017 . Highlights and achievements in 2017 and to date: Continued
Toggle Summary02/27/18 BioLineRx to Report Annual 2017 Results on March 6, 2018
Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel, Feb. 27, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will release its audited annual financial results for
Toggle Summary02/27/18 BioLineRx to Report Annual 2017 Results on March 6, 2018
Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel, Feb. 27, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will release its audited annual financial results for
Toggle Summary02/06/18 BioLineRx to Present at 2018 BIO CEO & Investor Conference in New York on February 13
TEL AVIV, Israel , Feb. 6, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief Executive Officer, Philip Serlin , will present a company update at the 2018 BIO CEO & Investor
Toggle Summary02/06/18 BioLineRx to Present at 2018 BIO CEO & Investor Conference in New York on February 13
TEL AVIV, Israel , Feb. 6, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief Executive Officer, Philip Serlin , will present a company update at the 2018 BIO CEO & Investor
Toggle Summary01/23/18 BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cells
TEL AVIV , Israel , January 23, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) (TASE: BLRX.TA) a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the publication of data showing that BL-8040, its lead oncology platform, augments the
Toggle Summary01/23/18 BioLineRx Reports Data at ASCO-SITC Conference Showing Complete Tumor Regression by AGI-134 in Pre-Clinical Studies
- AGI-134 on track to commence Phase 1/2a clinical study in H1 2018 - TEL AVIV, Israel , January 23, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) (TASE: BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that AGI-134, an
Toggle Summary01/17/18 BioLineRx Announces Partial Monotherapy Results from Phase 2a COMBAT Study in Pancreatic Cancer
- BL-8040 monotherapy resulted in increased infiltration of T cells into tumor - - Data to be presented at the upcoming ASCO-GI conference; topline clinical results expected by H2 2018 as planned - TEL AVIV , Israel , Jan. 17, 2018 /PRNewswire/ --  BioLineRx Ltd.
Toggle Summary12/21/17 BioLineRx Announces Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients
Study will assess mobilization of hematopoietic stem cells by BL-8040 compared to placebo, on top of G-CSF, for autologous transplantation in multiple myeloma patients TEL AVIV, Israel , December 21, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical
Toggle Summary12/05/17 BioLineRx Ltd. Hosts Investor Breakfast Meeting in NY
TEL AVIV, Israel , Dec. 5, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today hosts its investor breakfast meeting at the Convene Conference Center near Grand Central in New York, NY .
Toggle Summary12/05/17 BioLineRx Ltd. Hosts Investor Breakfast Meeting in NY
TEL AVIV, Israel , Dec. 5, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today hosts its investor breakfast meeting at the Convene Conference Center near Grand Central in New York, NY .
Toggle Summary12/04/17 BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML
BL-8040 in combination with high-dose Ara-C significantly improved overall survival compared to historical data TEL AVIV, Israel , December 4, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced
Toggle Summary11/21/17 BioLineRx Reports Third Quarter 2017 Financial Results
TEL AVIV, Israel , Nov. 21, 2017 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the third quarter ended September 30, 2017 . Highlights and achievements during the third
Toggle Summary11/20/17 BioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 Gastrointestinal Cancers Symposium
Enrollment to COMBAT study has been completed; full topline results expected in H2 2018 as planned TEL AVIV, Israel , November 20, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that an
Toggle Summary11/16/17 BioLineRx Ltd. to Host Investor Breakfast Meeting December 5, 2017 in New York
TEL AVIV, Israel , November 16, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will host an investor breakfast meeting on Tuesday, December 5, 2017 at the Convene Conference
Toggle Summary11/09/17 BioLineRx to Report Third Quarter 2017 Results on November 21, 2017
Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel , November 9, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its unaudited financial results
Toggle Summary11/02/17 BioLineRx Announces Oral Presentation at ASH of Data Supporting BL-8040 as Robust Mobilizer of Hematopoietic Stem Cells (HSC) Associated with Long-Term Engraftment
- Preclinical data demonstrate that BL-8040 mobilizes a significant number of these HSCs compared to G-CSF, thus potentially improving graft quality - TEL AVIV, Israel , November 2, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company focused on
Toggle Summary10/18/17 BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under Immunotherapy Collaboration
Combination trial of BL-8040 and atezolizumab is part of initiative for the development of novel cancer immunotherapy combinations TEL AVIV, Israel , October 18, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and
Toggle Summary09/26/17 BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy Collaboration
The BATTLE trial will investigate the combination of BL-8040 and atezolizumab under cancer immunotherapy collaboration TEL AVIV, Israel , September 26, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology,
Toggle Summary09/07/17 BioLineRx to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York
TEL AVIV, Israel , September 7, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that its Chief Executive Officer, Philip Serlin , and its Chief Business Officer, David Malek , will present
Toggle Summary08/21/17 BioLineRx Announces Regulatory Submission of Phase 3 Registrational Study for BL-8040 in Stem Cell Mobilization
- GENESIS is a Phase 3 trial for the mobilization of hematopoietic stem cells for autologous transplantation in patients with multiple myeloma - - Initiation of study expected by end of 2017 - TEL AVIV , Israel , Aug 21, 2017 /PRNewswire/ -- BioLineRx Ltd.
Toggle Summary08/08/17 BioLineRx Reports Second Quarter 2017 Financial Results
TEL AVIV, Israel , Aug. 8, 2017 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the second quarter ended June 30, 2017 . Highlights and achievements during the second quarter
Toggle Summary08/02/17 BioLineRx to Report Second Quarter 2017 Results on August 8, 2017
Management to hold conference call at 10:00 a.m. EDT TEL AVIV, Israel , August 2, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its unaudited financial results for
Toggle Summary07/26/17 BioLineRx Announces Additional Investment From BVF Partners L.P.
TEL AVIV, Israel , July 26, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that BVF Partners L.P. (BVF), its largest shareholder, has entered into a definitive agreement to make an
Toggle Summary07/10/17 BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration
Combination trial of BL-8040 and atezolizumab are part of initiative for the development of novel cancer immunotherapy combinations TEL AVIV, Israel , July 10, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology,
Toggle Summary06/01/17 BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination With Atezolizumab for Solid Tumors
TEL AVIV, Israel , June 1, 2017 /PRNewswire/ -- - Genentech has submitted all three solid tumor trials planned under it s cancer immunotherapy collaboration with BioLineRx -   - Studies will investigate the combination in pancreatic cancer,   gastric cancer and non-small cell lung cancer (NSCLC) -
Toggle Summary05/25/17 BioLineRx Reports First Quarter 2017 Financial Results
TEL AVIV, Israel , May 25, 2017 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the first quarter ended March 31, 2017 . Highlights and achievements during the first quarter
Toggle Summary05/22/17 BioLineRx Announces Regulatory Submission for Phase 1b Trial of BL-8040 in Combination with Atezolizumab in AML
Phase 1b trial under cancer immunotherapy collaboration with Genentech TEL AVIV, Israel , May 22, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the filing of regulatory submissions
Toggle Summary05/16/17 BioLineRx to Report First Quarter 2017 Results on May 25, 2017
Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , May 16, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its unaudited financial results for the
Toggle Summary05/03/17 BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA
TEL AVIV, Israel , May 3, 2017 /PRNewswire/ -- - Initiation of Phase 3 registrational study expected in second half of this year  - Study to focus on stem cell mobilization for autologous transplantation in multiple myeloma patients BioLineRx Ltd. (NASDAQ/TASE: BLRX, BLRX.TA), a clinical-stage
Toggle Summary04/05/17 BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares
TEL AVIV, Israel , April 5, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical stage biopharmaceutical development company focused on oncology and immunology, today announced that it has closed its previously announced underwritten public offering of approximately 33.8 million
Toggle Summary03/31/17 BioLineRx Prices $25 Million Underwritten Public Offering
TEL AVIV, Israel , March 31, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical stage biopharmaceutical development company focused on oncology and immunology, today announced that it has priced an underwritten public offering of approximately 29.4 million American Depositary
Toggle Summary03/30/17 BioLineRx Announces Underwritten Public Offering of its American Depositary Shares
TEL AVIV, Israel , March 30, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical stage biopharmaceutical development company focused on oncology and immunology, today announced that it has commenced an underwritten public offering of American Depositary Shares ("ADSs"), each
Toggle Summary03/27/17 BioLineRx's AGI-134 to be Presented at AACR 2017
TEL AVIV, Israel , March 27, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that AGI-134, an immunotherapy for the treatment of multiple cancers, obtained through its recently announced
Toggle Summary03/23/17 BioLineRx Reports Year End 2016 Financial Results
TEL AVIV, Israel , March 23, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX,  TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the year ended December 31, 2016 . Highlights and achievements in 2016 and to date:
Toggle Summary03/23/17 BioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of Immuno-Oncology Pipeline
Agalimmune's Lead Asset, AGI-134, Provides a Unique Approach for Eliciting Patient-specific, Anti-tumor Immune Responses in Multiple Cancer Types TEL AVIV, Israel , March 23, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and
Toggle Summary03/20/17 BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment
TEL AVIV, Israel , March 20, 2017 /PRNewswire/ -- - Results to date confirm that s ingle injection of BL-8040   mobilize s sufficient amounts of cells required for   allogeneic transplantation without need for G-CSF -   - Top -l ine results expected by end of 201 7 -   BioLineRx Ltd.
Toggle Summary03/16/17 BioLineRx to Report Annual 2016 Results on March 23, 2017
Management to hold a conference call at 9:00 a.m. EDT TEL AVIV, Israel , March 16, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its audited annual financial results for
Toggle Summary02/07/17 BioLineRx to Present at 2017 BIO CEO & Investor Conference in New York on February 14
TEL AVIV, Israel , February 7, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief Executive Officer, Philip Serlin , and its Chief Business Officer, David Malek , will present a
Toggle Summary01/17/17 BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
Study is part of strategic research collaboration between MSD and MD Anderson Cancer Center aimed to evaluate KEYTRUDA in selected GI tumors using various combinations TEL AVIV, Israel , January 17, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical
Toggle Summary01/04/17 BioLineRx to Present at Biotech Showcase 2017 Conference in San Francisco
TEL AVIV, Israel , January 4, 2017 /PRNewswire/ -- BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Philip Serlin , will be presenting
Toggle Summary12/05/16 BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016
TEL AVIV, Israel , December 5, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase 2a correlative data, as well as detailed
Toggle Summary11/22/16 BioLineRx Reports Third Quarter 2016 Financial Results
TEL AVIV, Israel , Nov. 22, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the third quarter ended September
Toggle Summary11/21/16 BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic Collaboration with Major Global Pharmaceutical Company
Therapeutic compound is third project in-licensed under strategic collaboration with Novartis for screening and development of novel drug candidates TEL AVIV, Israel , November 21, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to
Toggle Summary11/15/16 BioLineRx to Report Third Quarter Results on November 22, 2016
Management to hold conference call at 10:00 a.m. EST TEL AVIV, Israel , November 15, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it
Toggle Summary11/03/16 BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016
TEL AVIV, Israel , November 3, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, disclosed today positive Phase 2a correlative data, as well as detailed
Toggle Summary10/05/16 BioLineRx Announces Acceptance of BL-8040 Abstracts for Oral and Poster Presentations at 58th American Society of Hematology (ASH) Annual Meeting
TEL AVIV, Israel , October 5, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that data on BL-8040, the Company's leading oncology platform,
Toggle Summary09/23/16 BioLineRx Announces In-licensing of Novel Treatment for Liver Failure Conditions Under Strategic Collaboration
Therapeutic compound is second project in-licensed under strategic collaboration with Novartis for screening and development of novel drug candidates TEL AVIV, Israel , September 23, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to
Toggle Summary09/22/16 BioLineRx Ltd. Presents Corporate Objectives at Investor Breakfast Meeting in NY
- Presentation includes details of 2017 operating plan and five-year Company vision - TEL AVIV, Israel , September 22, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic
Toggle Summary09/20/16 BioLineRx Announces Initiation of Phase 2a Trial of BL-8040 in Combination With KEYTRUDA® (pembrolizumab) for Treatment of Pancreatic Cancer
TEL AVIV, Israel , September 20, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE:BLRX) today announced the initiation of a Phase 2a trial investigating BL-8040 in combination with KEYTRUDA ® (pembrolizumab), MSD's anti-PD-1 therapy, in patients with metastatic pancreatic cancer.
Toggle Summary09/09/16 BioLineRx Ltd. to Host Investor Breakfast Meeting September 22, 2016 in New York
TEL AVIV, Israel , September 9, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE : BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will host an investor breakfast meeting on Thursday,
Toggle Summary09/08/16 BioLineRx Presents Final Results from Phase 2a Trial for Relapsed/Refractory AML at SOHO Conference
Combination of BL-8040 with Ara-C in difficult-to-treat patient population demonstrated substantial improvement over clinical response rates historically achieved with Ara-C TEL AVIV, Israel , September 8, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced that the successful final
Toggle Summary09/07/16 BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications
Cancer immunotherapy collaboration with Genentech includes several Phase 1b combination studies for multiple solid tumor indications and AML TEL AVIV, Israel , September 7, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX) today announced that it has entered into a collaboration with
Toggle Summary08/29/16 BioLineRx to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York
TEL AVIV, Israel , August 29, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Financial and Operating Officer, Philip
Toggle Summary08/25/16 BioLineRx and I-Bridge Capital Establish a New Drug Development Joint Venture in China
JV will promote development and commercialization of Israeli-sourced therapeutic assets for Chinese healthcare market TEL AVIV, Israel , August 25, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and
Toggle Summary08/11/16 BioLineRx Reports Second Quarter 2016 Financial Results
TEL AVIV, Israel , Aug. 11, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the second quarter ended June 30,
Toggle Summary08/11/16 BioLineRx Names Philip A. Serlin as Chief Executive Officer
TEL AVIV, Israel , August 11, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Philip A.
Toggle Summary08/08/16 BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
- Phase 2 study is part of strategic clinical research collaboration between MSD and MD Anderson Cancer Center aimed at evaluating KEYTRUDA in selected GI tumors using various combinations - TEL AVIV, Israel , August 8, 2016 /PRNewswire/ -- BioLineRx Ltd.
Toggle Summary08/04/16 BioLineRx to Report Second Quarter Results on August 11, 2016
Management to hold conference call at 10:00 a.m. EDT TEL AVIV, Israel , August 4, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will
Toggle Summary08/01/16 BioLineRx Announces In-licensing of Liver Fibrosis Project Under Strategic Collaboration
Novel drug candidate modulates immune system to reduce liver fibrosis in non-alcoholic steatohepatitis TEL AVIV, Israel , August 1, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising
Toggle Summary06/28/16 BioLineRx Announces Regulatory Submissions for Phase 2a Trial of BL-8040 in Combination with KEYTRUDA® (pembrolizumab) for Treatment of Pancreatic Cancer
- Study expected to commence during Q3 2016 -   TEL AVIV, Israel , June 28, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the filing of
Toggle Summary06/15/16 BioLineRx to Present at the JMP Securities Life Sciences Conference in New York
TEL AVIV , Israel , June 15, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky ,
Toggle Summary05/19/16 BioLineRx's BL-8040 to be Presented at Upcoming Scientific Conferences
TEL AVIV, Israel , May 19, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that BL-8040, its lead platform for the treatment of multiple cancer and hematological indications, will be presented at two upcoming scientific conferences.
Toggle Summary05/17/16 BioLineRx Reports First Quarter 2016 Financial Results
TEL AVIV, Israel , May 17, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the first quarter ended March 31, 2016 .
Toggle Summary05/16/16 BioLineRx and MaRS Innovation Sign Framework Collaboration Agreement
TEL AVIV, Israel , May 16, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX ), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a framework collaboration agreement with MaRS
Toggle Summary05/10/16 BioLineRx to Report First Quarter 2016 Results on May 17, 2016
Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , May 10, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX ), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will
Toggle Summary04/19/16 BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at AACR 2016
- Results identify specific targets in the apoptotic pathway - TEL AVIV, Israel , April 19, 2016 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that detailed results from a study on the underlying mechanism of action of BL-8040, its lead platform for the treatment of multiple
Toggle Summary04/04/16 BioLineRx's Novel Treatment for Non-Surgical Removal of Skin Lesions Receives CE Mark Approval
TEL AVIV, Israel , April 4, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that its partner, Omega Pharma, now part of Perrigo , has received CE Mark approval for BL-5010 as a novel OTC treatment for the non-surgical removal of skin lesions.
Toggle Summary03/29/16 BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML
Data identify a potential biomarker for future selection of BL-8040-responsive AML patients TEL AVIV, Israel , March 29, 2016 /PRNewswire/ -- BioLineRx (NASDAQ/TASE: BLRX) announced today positive top-line results from BL-8040's Phase 2 clinical trial in relapsed or refractory acute myeloid
Toggle Summary03/23/16 BioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment
Partial results expected by end of 2016 TEL AVIV, Israel , March 23, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE:BLRX) announced today the initiation of a Phase 2 trial for BL-8040 as a novel approach for the mobilization and collection of bone marrow stem cells from the peripheral blood
Toggle Summary03/10/16 BioLineRx Reports Year End 2015 Financial Results
TEL AVIV, Israel , March 10, 2016 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the year ended December 31, 2015 .
Toggle Summary03/10/16 BioLineRx to Present at 2016 Annual Roth Conference in Southern California on March 14
TEL AVIV, Israel , March 10, 2016 /PRNewswire/ -- BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its
Toggle Summary03/03/16 BioLineRx to Report Annual 2015 Results on March 10, 2016
Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel , March 3, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it
Toggle Summary02/01/16 BioLineRx to Present at 2016 BIO CEO & Investor Conference in New York on February 8
TEL AVIV, Israel , February 1, 2016 /PRNewswire/ -- BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its
Toggle Summary01/25/16 BioLineRx Receives Confirmation of Medical Device Classification in Europe for Celiac Treatment
BL-7010 receives designation as Class IIb medical device TEL AVIV, Israel , January 25, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it
Toggle Summary01/12/16 BioLineRx Announces Collaboration with MSD to Investigate the Combination of KEYTRUDA (pembrolizumab) and BL-8040 in Pancreatic Cancer
BioLineRx management to hold conference call this morning at 10:00 am EST to further discuss this immunotherapy collaboration TEL AVIV, Israel , January 12, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX) today announced a collaboration with MSD, known as Merck in the US and Canada , to
Toggle Summary01/04/16 BioLineRx to Present at Biotech Showcase 2016 Conference in San Francisco
TEL AVIV, Israel , January 4, 2016 /PRNewswire/ -- BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its
Toggle Summary12/14/15 BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Stem Cell Mobilization Treatment
Study will be conducted in collaboration with Washington University School of Medicine , Division of Hematology and Oncology TEL AVIV, Israel --(BUSINESS WIRE)--Dec. 14, 2015-- BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and
Toggle Summary12/03/15 BioLineRx Establishes Oncology Scientific Advisory Board
TEL AVIV, Israel --(BUSINESS WIRE)--Dec. 3, 2015-- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported the establishment of a Scientific Advisory Board (SAB) to provide
Toggle Summary11/25/15 BioLineRx Ltd. to Host Investor Breakfast in New York on December 3, 2015
TEL AVIV, Israel --(BUSINESS WIRE)--Nov. 25, 2015-- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it will host an investor breakfast on Thursday, December 3,
Toggle Summary11/24/15 BioLineRx to Present at the LD Micro Main Event
TEL AVIV, Israel --(BUSINESS WIRE)--Nov. 24, 2015-- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D.,
Toggle Summary11/23/15 BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions
Efficacy and safety study, in collaboration with MD Anderson Cancer Center , will assess BL-8040 as combination treatment with immunosuppressants Interim results of study, in patients with hypoplastic myelodysplastic syndrome (hMDS) and aplastic anemia (AA), expected by end of 2016 TEL AVIV, Israel
Toggle Summary11/16/15 BioLineRx Reports Third Quarter 2015 Financial Results
TEL AVIV, Israel --(BUSINESS WIRE)--Nov. 16, 2015-- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the third quarter ended September 30,
Toggle Summary11/09/15 BioLineRx to Report Third Quarter 2015 Results on November 16, 2015
Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel --(BUSINESS WIRE)--Nov. 9, 2015-- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it
Toggle Summary11/05/15 BioLineRx Announces Positive Clinical Results from First Part of Phase 2 Trial in r/r AML
- Data strongly suggest BL-8040 has potent anti-leukemic activity in combination with Ara-C in AML - - Results to be presented at 2015 ASH Annual Meeting - TEL AVIV, Israel --(BUSINESS WIRE)--Nov. 5, 2015-- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to
Toggle Summary09/10/15 BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Treatment for Hypoplastic Myelodysplastic Syndrome and Aplastic Anemia
Study collaboration with MD Anderson Cancer Center will assess BL-8040 as combination treatment with immunosuppressants TEL AVIV, Israel --(BUSINESS WIRE)--Sep. 10, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing
Toggle Summary09/09/15 BioLineRx’s Novel Treatment for Non-Surgical Removal of Skin Lesions Submitted for CE Mark Registration
- Product expected to reach the market in 2016 - TEL AVIV, Israel --(BUSINESS WIRE)--Sep. 9, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its
Toggle Summary09/03/15 BioLineRx to Present at the 17th Annual Rodman & Renshaw Global Investment Conference in New York
TEL AVIV, Israel --(BUSINESS WIRE)--Sep. 3, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky ,
Toggle Summary08/20/15 BioLineRx Reports Second Quarter 2015 Financial Results
TEL AVIV, Israel --(BUSINESS WIRE)--Aug. 20, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the second quarter ended June
Toggle Summary08/17/15 BioLineRx Announces Initiation of Phase 2b Trial for Novel AML Consolidation Treatment
- Phase 2b study, as consolidation treatment for AML patients responding to standard induction treatment, will enroll up to 194 patients, randomized in 1:1 ratio, at up to 25 sites in Germany - - Study is first of three additional clinical studies for BL-8040 platform expected to commence during
Toggle Summary08/13/15 BioLineRx to Report Second Quarter 2015 Results on August 20, 2015
Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel --(BUSINESS WIRE)--Aug. 13, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today
Toggle Summary07/27/15 BioLineRx Announces Top-Line Results from Bellerophon’s PRESERVATION I Clinical Trial for Bioabsorbable Cardiac Matrix (BL-1040)
TEL AVIV, Israel --(BUSINESS WIRE)--Jul. 27, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its partner, Bellerophon, reported top-line results
Toggle Summary06/17/15 BioLineRx to Present Successful Results of Phase 1/2 Study for Novel Celiac Treatment at International Celiac Disease Symposium
TEL AVIV, Israel --(BUSINESS WIRE)--Jun. 17, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will present positive safety results of its Phase
Toggle Summary06/16/15 BioLineRx to Present at the JMP Securities Life Sciences Conference in New York
TEL AVIV, Israel --(BUSINESS WIRE)--Jun. 16, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Financial and Operating Officer, Philip
Toggle Summary06/15/15 BioLineRx Presents Positive Safety and Efficacy Results for Novel Stem-Cell Mobilization Treatment at European Hematology Association Conference
BL-8040’s rapid stem-cell mobilization supports stand-alone one-day treatment for stem-cell collection Graft derived from BL-8040 treatment shows unique cell composition TEL AVIV, Israel --(BUSINESS WIRE)--Jun. 15, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical
Toggle Summary06/03/15 Research Underlying BioLineRx’s Treatment of Type 1 Diabetes Wins Hebrew University's Kaye Innovation Award
TEL AVIV, Israel --(BUSINESS WIRE)--Jun. 3, 2015-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that research underlying BL-9020, for the treatment of Type 1
Toggle Summary06/01/15 BioLineRx Announces Peer-Reviewed Publication of Phase 1/2 Trial Results for Novel Treatment for Non-Surgical Removal of Skin Lesions
- Previously reported results published in British Journal of Dermatology - JERUSALEM --(BUSINESS WIRE)--Jun. 1, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates,
Toggle Summary05/27/15 BioLineRx to Present Positive Safety and Efficacy Clinical Data for Novel Stem Cell Mobilization Treatment at the European Hematology Annual Congress
JERUSALEM --(BUSINESS WIRE)--May 27, 2015-- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE: BLRX ), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that positive safety and efficacy Phase 1 clinical data of its
Toggle Summary05/18/15 BioLineRx Reports First Quarter 2015 Financial Results
JERUSALEM --(BUSINESS WIRE)--May 18, 2015-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the first quarter ended March 31, 2015 .
Toggle Summary05/11/15 BioLineRx to Report First Quarter 2015 Results on May 18, 2015
Management to hold a conference call at 10:00 a.m. EDT JERUSALEM --(BUSINESS WIRE)--May 11, 2015-- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE: BLRX ), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it
Toggle Summary05/04/15 BioLineRx Initiates Expansion Stage of Phase 2 Clinical Trial for Novel Treatment for Acute Myeloid Leukemia
BL-8040 remains safe and well tolerated at highest dose; continues to induce robust mobilization and leukemia cell death Top-line results expected Q4 2015 JERUSALEM --(BUSINESS WIRE)--May 4, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to
Toggle Summary03/25/15 BioLineRx Reports Successful Top-Line Safety and Efficacy Results for Novel Stem Cell Mobilization Treatment
- BL-8040 Phase 1 study met all safety and efficacy endpoints - - High stem-cell yield supports novel single-day collection procedure - JERUSALEM --(BUSINESS WIRE)--Mar. 25, 2015-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying,
Toggle Summary03/23/15 BioLineRx Reports Year End 2014 Financial Results
JERUSALEM --(BUSINESS WIRE)--Mar. 23, 2015-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the year ended December 31, 2014 .
Toggle Summary03/17/15 BioLineRx to Report Fourth Quarter and Year End 2014 Results on March 23, 2015
- Management to hold conference call at 10:00 a.m. EDT - JERUSALEM --(BUSINESS WIRE)--Mar. 17, 2015-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that
Toggle Summary03/11/15 BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares
JERUSALEM --(BUSINESS WIRE)--Mar. 11, 2015-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has closed its previously announced underwritten public
Toggle Summary03/11/15 BioLineRx’s Treatment for Type 1 Diabetes Effective in Preclinical Trials
- Results of experiments with BL-9020, a new antibody treatment, published in PLoS One - JERUSALEM --(BUSINESS WIRE)--Mar. 11, 2015-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic
Toggle Summary03/06/15 BioLineRx to Present at the Annual Roth Conference in California
JERUSALEM --(BUSINESS WIRE)--Mar. 6, 2015-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its
Toggle Summary03/06/15 BioLineRx Prices $25 Million Underwritten Public Offering of its American Depositary Shares
JERUSALEM --(BUSINESS WIRE)--Mar. 6, 2015-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has priced an underwritten public offering of 12,500,000
Toggle Summary03/05/15 BioLineRx Announces Underwritten Public Offering of its American Depositary Shares
JERUSALEM , March 5, 2015 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has commenced an underwritten public offering of American
Toggle Summary03/02/15 BioLineRx Announces Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment
- BL-8040 Phase 2b study, as consolidation treatment for AML patients responding to standard induction treatment, is expected to commence shortly after receipt of regulatory approval, anticipated in next few months - JERUSALEM --(BUSINESS WIRE)--Mar. 2, 2015-- BioLineRx Ltd.
Toggle Summary02/03/15 BioLineRx to Present at 2015 BIO CEO & Investor Conference in New York on February 10
JERUSALEM --(BUSINESS WIRE)--Feb. 3, 2015-- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its
Toggle Summary01/14/15 BioLineRx Announces Completion of Enrollment in CE Mark Registration Trial of BCM (BL-1040), a Novel Medical Device for Prevention of Cardiac Remodeling Following Acute Myocardial Infarction
- PRESERVATION I trial completion anticipated in mid-2015 - JERUSALEM --(BUSINESS WIRE)--Jan. 14, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that
Toggle Summary01/06/15 BioLineRx Completes Dose Escalation Stage of Phase 1 Trial for Novel Stem Cell Mobilization Treatment
- Results of Phase 1 trial for BL-8040 expected in Q1 2015 - - Multiple additional clinical milestones for BL-8040 anticipated in 2015 - JERUSALEM --(BUSINESS WIRE)--Jan. 6, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying,
Toggle Summary01/06/15 BioLineRx to Present at Biotech Showcase 2015 Conference in San Francisco
JERUSALEM --(BUSINESS WIRE)--Jan. 6, 2015-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its
Toggle Summary12/23/14 BioLineRx Out-Licenses Novel Skin Lesion Treatment to Omega Pharma
- Omega Pharma to develop and commercialize novel skin treatment for OTC use in Europe and additional selected countries - - First product expected to reach the market in 2016 - JERUSALEM --(BUSINESS WIRE)--Dec. 23, 2014-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage
Toggle Summary12/16/14 BioLineRx and Major Global Pharmaceutical Company Form Strategic Collaboration for Screening and Development of Novel Drug Candidates
- Global pharmaceutical company makes initial $10 million equity investment in BioLineRx - - BioLineRx to host conference call today, December, 16 at 10:00 a.m. EST - JERUSALEM --(BUSINESS WIRE)--Dec. 16, 2014-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company
Toggle Summary12/12/14 BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic Platform
- Clinical trials in three additional indications for BL-8040 to be initiated in 2015 - - Development strategy presented today at BioLineRx investor meeting in New York - NEW YORK --(BUSINESS WIRE)--Dec. 12, 2014-- During an investor and analyst meeting hosted today in New York , BioLineRx Ltd.
Toggle Summary12/08/14 BioLineRx Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH Conference
- Data show six-fold increase in mobilization of AML cells from bone marrow; Treatment with BL-8040 as single agent led to 70% decrease in AML cells in bone marrow and 3.5-fold increase in AML cell apoptosis - JERUSALEM --(BUSINESS WIRE)--Dec. 8, 2014-- BioLineRx Ltd.
Toggle Summary11/10/14 BioLineRx Reports Third Quarter 2014 Financial Results
JERUSALEM--(BUSINESS WIRE)--Nov. 10, 2014-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the third quarter ended September 30, 2014 .
Toggle Summary11/05/14 BioLineRx Announces Successful Final Results of Phase 1/2 Study for Novel Celiac Treatment
- Optimal safe dose of BL-7010 determined for upcoming randomized efficacy study - - Lack of systemic exposure of BL-7010 likely supports medical-device classification in Europe - JERUSALEM --(BUSINESS WIRE)--Nov. 5, 2014-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage
Toggle Summary11/03/14 BioLineRx to Report Third Quarter 2014 Results on November 10, 2014
- Management to hold conference call at 10:00 a.m. EST - JERUSALEM --(BUSINESS WIRE)--Nov. 3, 2014-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it
Toggle Summary11/03/14 BioLineRx Files Protocol Amendment to Phase 2 Study for AML Treatment based on Encouraging Efficacy and Strong Safety Profile
- Amendment will include testing of higher doses, resulting in increase of total study population to up to 70 patients - - Changes unanimously recommended by Clinical Advisory Board - JERUSALEM --(BUSINESS WIRE)--Nov. 3, 2014-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage
Toggle Summary10/31/14 BioLineRx Reports Publication in Peer Review Journal of Results from Previous Phase 1/2 Trial for BCM (BL-1040), a Novel Medical Device for Prevention of Cardiac Remodeling Following Acute Myocardial Infarction
- Results of first-in-man study published in Circulation: Cardiovascular Interventions - - BCM (BL-1040) is currently undergoing PRESERVATION I, a CE Mark registration trial conducted by Bellerophon, with study completion anticipated in mid-2015 - JERUSALEM --(BUSINESS WIRE)--Oct.
Toggle Summary09/17/14 BioLineRx Presents Positive Preclinical Results in Treatment for AML Patients with FLT3 Mutations
- Results in this additional indication for BL-8040 presented at Society of Hematologic Oncology (SOHO) Annual Meeting - - BL-8040 also undergoing Phase 2 study in AML, with final results expected in early 2015; and Phase 1 study in stem cell mobilization, with results expected by year-end 2014 or
Toggle Summary09/03/14 BioLineRx Doses First Patient for BL-8040’s Second Indication as Novel Stem Cell Mobilization Treatment
Results from Phase 1 trial expected by end of 2014 or early 2015; BL-8040 also in midst of Phase 2 trial for AML, with results expected in early 2015 JERUSALEM --(BUSINESS WIRE)--Sep. 3, 2014-- BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to
Toggle Summary09/02/14 BioLineRx to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York
JERUSALEM --(BUSINESS WIRE)--Sep. 2, 2014-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and
Toggle Summary08/21/14 BioLineRx Receives Notice of Allowance for US Patent on BL-7010 Covering Use of Novel Polymer in Prevention of Gluten Toxicity
- BL-7010 for treatment of celiac disease is currently in final stages of Phase 1/2 safety study; efficacy study expected to commence in early 2015 - JERUSALEM --(BUSINESS WIRE)--Aug. 21, 2014-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to
Toggle Summary08/06/14 BioLineRx Reports Second Quarter 2014 Financial Results
JERUSALEM --(BUSINESS WIRE)--Aug. 6, 2014-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the second quarter ended June 30, 2014 .
Toggle Summary07/30/14 BioLineRx to Report Second Quarter 2014 Results on August 6, 2014
Management to hold a conference call at 10:00 a.m. EDT JERUSALEM --(BUSINESS WIRE)--Jul. 30, 2014-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it
Toggle Summary07/16/14 BioLineRx Announces Results from Phase 1/2 Study for Celiac Treatment
BL-7010 well tolerated in both single- and repeated-dose administrations Supports classification as medical device in Europe due to lack of systemic absorption Company to investigate lower doses of BL-7010 prior to commencing efficacy study expected in early 2015 JERUSALEM --(BUSINESS WIRE)--Jul.
Toggle Summary06/23/14 BioLineRx In-Licenses Novel Compound for Treatment of Neuropathic Pain
BL-1110 was shown in preclinical studies to enhance analgesic effect of morphine while reducing negative side effects BL-1110 may also be developed for scleroderma JERUSALEM --(BUSINESS WIRE)--Jun. 23, 2014-- BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a clinical-stage biopharmaceutical company
Toggle Summary06/16/14 BioLineRx Receives Approval to Commence Phase 1 Trial for Novel Stem Cell Mobilization Treatment
Phase 1 trial of BL-8040 expected to begin in Q3 2014; results expected in late 2014 or early 2015 BL-8040 also in Phase 2 for AML; results expected in early 2015 JERUSALEM --(BUSINESS WIRE)--Jun. 16, 2014-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company
Toggle Summary06/11/14 BioLineRx Receives Notice of Allowance for US Patent Covering Novel Treatment for Celiac Disease
Results of ongoing Phase 1/2 trial for BL-7010 expected in next few weeks JERUSALEM --(BUSINESS WIRE)--Jun. 11, 2014-- BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates,
Toggle Summary05/30/14 BioLineRx Enters into Share Purchase Agreement with Lincoln Park Capital
JERUSALEM --(BUSINESS WIRE)--May 30, 2014-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a purchase agreement for the sale, from time to
Toggle Summary05/20/14 BioLineRx Reports First Quarter 2014 Financial Results
Company Poised to Execute on Multiple Clinical Milestones JERUSALEM --(BUSINESS WIRE)--May 20, 2014-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its
Toggle Summary05/15/14 BioLineRx to Report First Quarter 2014 Results on May 20, 2014
Management to hold a conference call at 10:00 a.m. EDT JERUSALEM --(BUSINESS WIRE)--May 15, 2014-- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE: BLRX ), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it
Toggle Summary04/10/14 BioLineRx Announces Investigator-Initiated Study for Novel Chronic Myeloid Leukemia Treatment
Phase 1/2 study will assess effect of BL-8040 in combination with standard therapy JERUSALEM --(BUSINESS WIRE)--Apr. 10, 2014-- BioLineRx (NASDAQ: BLRX)(TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates,
Toggle Summary03/17/14 BioLineRx Reports Year End 2013 Financial Results
JERUSALEM --(BUSINESS WIRE)--Mar. 17, 2014-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the year ended December 31, 2013 .
Toggle Summary03/14/14 BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 in Immunotherapy
- BL-8040 currently undergoing Phase 2 trial for acute myeloid leukemia (AML), and expected to commence Phase 1 trial in stem cell mobilization in Q2 2014 - - Top-line results from both trials expected in next 9-12 months - JERUSALEM --(BUSINESS WIRE)--Mar. 14, 2014-- BioLineRx Ltd.
Toggle Summary03/11/14 BioLineRx to Report Fourth Quarter and Year End 2013 Results on March 17, 2014
- Management to hold conference call at 10:00 a.m. EDT - JERUSALEM --(BUSINESS WIRE)--Mar. 11, 2014-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that
Toggle Summary03/10/14 BioLineRx Completes Dose Escalation Stage of Phase 1/2 Study for Novel Celiac Treatment
Single administration of BL-7010 was safe and well tolerated at all doses tested BL-7010 now advancing to repeated administration part of study; results expected mid 2014 JERUSALEM --(BUSINESS WIRE)--Mar. 10, 2014-- BioLineRx (NASDAQ: BLRX)(TASE: BLRX), a clinical-stage biopharmaceutical company
Toggle Summary03/07/14 BioLineRx Closes $24.1 Million Underwritten Public Offering of its American Depositary Shares
JERUSALEM--(BUSINESS WIRE)--Mar. 7, 2014-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has closed its previously announced underwritten public
Toggle Summary03/05/14 BioLineRx to Present at the Annual ROTH Growth Stock Conference in California
JERUSALEM--(BUSINESS WIRE)--Mar. 5, 2014-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its
Toggle Summary03/04/14 BioLineRx Prices $21.0 Million Underwritten Public Offering of its American Depositary Shares
Jerusalem, March 4, 2014 - BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has priced an underwritten public offering of 8,400,000 American Depositary
Toggle Summary03/03/14 BioLineRx Announces Underwritten Public Offering of its American Depositary Shares
JERUSALEM, March 3, 2014 /PRNewswire/ --  BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has commenced an underwritten public offering of its American
Toggle Summary02/24/14 BioLineRx Appoints Dr. Sandra Panem to Board of Directors
JERUSALEM , Feb. 24, 2014 /PRNewswire/ --  BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the appointment of Sandra Panem , Ph.D., to its Board of Directors.
Toggle Summary02/12/14 BioLineRx Announces Positive Preclinical Results for Novel Treatment for Chronic Myeloid Leukemia
- BL-8040 study published in Molecular Cancer Therapeutics - - BL-8040 currently undergoing Phase 2 trial for acute myeloid leukemia (AML), and expected to commence Phase 1 trial in stem cell mobilization in Q2 2014; top-line results from both trials expected in Q4 2014 - JERUSALEM , Feb.
Toggle Summary02/03/14 BioLineRx to Present at the 2014 BIO CEO & Investor Conference in New York on February 10
JERUSALEM , Feb. 3, 2014 /PRNewswire/ --  BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its
Toggle Summary01/23/14 BioLineRx Receives Orphan Drug Designation for Novel Stem Cell Mobilization Treatment
- BL-8040 previously received Orphan Drug Designation for treatment of Acute Myeloid Leukemia - - BL-8040 expected to commence Phase 1 trial in stem cell mobilization in Q2 2014; top-line results expected in H2 2014 - JERUSALEM , Jan. 23, 2014 /PRNewswire/ --  BioLineRx (NASDAQ: BLRX; TASE: BLRX),
Toggle Summary01/21/14 BioLineRx Receives Approval to Commence Pivotal Trial for Novel Skin Lesion Treatment
- CE Mark registration trial for BL-5010P expected to begin H1 2014; results expected H2 2014 - JERUSALEM , Jan. 21, 2014 /PRNewswire/ --  BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic
Toggle Summary01/13/14 BioLineRx Announces Regulatory Submission for Novel Stem Cell Mobilization Treatment
Phase 1 Trial of BL-8040 expected to begin in Q2 2014; top-line results expected in H2 2014 BL-8040 is also in Phase 2 for AML; top-line results expected in H2 2014 JERUSALEM , Jan. 13, 2014 /PRNewswire/ --  BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated
Toggle Summary01/08/14 BioLineRx and JHL Biotech to Collaborate on Type 1 Diabetes Antibody Treatment
- JHL Biotech to develop and commercialize BL-9020 in China and additional Southeast Asia countries - JERUSALEM and HSINCHU, Taiwan , Jan. 8, 2014 /PRNewswire/ --  BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing
Toggle Summary01/07/14 BioLineRx to Present at Biotech Showcase Conference in San Francisco
JERUSALEM , Jan. 7, 2014 /PRNewswire/ --  BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its
Toggle Summary12/18/13 BioLineRx Enters Clinic with Novel Treatment for Celiac Disease
- Results of Phase 1/2 trial for BL-7010 expected in mid-2014 - JERUSALEM , Dec. 18, 2013 /PRNewswire/ --  BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today
Toggle Summary12/16/13 BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
- Initial results for BL-8040 show substantial mobilization of cancer cells and signs of robust cancer cell death (apoptosis) - JERUSALEM , Dec. 16, 2013 /PRNewswire/ --  BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and
Toggle Summary12/10/13 BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
BL-8040 is currently in midst of Phase 2 study in AML patients, with partial results expected this month and final results expected in H2 2014 - JERUSALEM , Dec. 10, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that positive
Toggle Summary11/26/13 BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
- New results show BL-7040 to reduce pro-inflammatory cytokine levels and improve colon histology in IBD patients BL-7040 was previously shown to be safe and effective in Phase 2a trial completed in Q2 2013 - (Logo:   http://photos.prnewswire.com/prnh/20130730/630769 ) Jerusalem, November 26, 2013
Toggle Summary11/19/13 BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
- Results published in Clinical Cancer Research - - Additional clinical trial in stem cell mobilization expected to commence in H1 2014 - JERUSALEM , Nov. 19, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today the publication of
Toggle Summary11/13/13 BioLineRx Reports Third Quarter 2013 Financial Results
JERUSALEM, Nov. 13, 2013 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, today reported its results for the third quarter ending September 30, 2013 . (Logo: http://photos.prnewswire.com/prnh/20130730/630769 ) Kinneret Savitsky , Ph.D., Chief
Toggle Summary11/06/13 BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
Management to hold conference call at 10:00 a.m. EST - JERUSALEM , Nov. 6, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it will release its unaudited financial results for the quarter ended September 30, 2013 on Wednesday,
Toggle Summary11/05/13 BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
JERUSALEM , Nov. 5, 2013 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced that it will host an Analyst & Investor Day on Thursday, November 21, 2013 in New York City beginning at 8:15 am EST .
Toggle Summary11/04/13 BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
- Study expected to begin by end of 2013 - - Results expected in mid-2014 - JERUSALEM , Nov. 4, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has received regulatory approval from the Finnish National Supervisory
Toggle Summary10/23/13 BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
Preclinical data show that BL-9020 prevents formation of Type 1 diabetes JERUSALEM , Oct. 23, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has signed a worldwide, exclusive license agreement with Yissum Research
Toggle Summary10/07/13 BioLineRx Announces Receipt of Notice of Allowance from USPTO for Patent Covering BL-5010, a Novel Treatment for Removal of Skin Lesions
JERUSALEM , Oct. 7, 2013 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application claiming the composition of
Toggle Summary09/24/13 BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
- Study expected to begin in Q4 2013 - - Results expected in mid-2014 - JERUSALEM , Sept. 24, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has filed the necessary regulatory submissions to commence a Phase 1/2 trial for
Toggle Summary09/17/13 BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
- Patent valid until at least 2031 - JERUSALEM , Sept. 17, 2013 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for BL-8020, an
Toggle Summary09/09/13 BioLineRx's BL-8040 Receives Orphan Drug Designation for Treatment of AML
JERUSALEM , Sept. 9, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that the U.S. Food & Drug Administration (FDA) has granted an Orphan Drug Designation to BL-8040 as a therapeutic for the treatment of acute myeloid leukemia
Toggle Summary09/03/13 BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
JERUSALEM , Sept. 3, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its Chief Financial and Operating Officer, Philip Serlin , will be presenting at the 15 th
Toggle Summary09/03/13 BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
JERUSALEM , Sept. 3, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that an Issue Notification has been received from the United States Patent and Trademark Office (USPTO) for US Patent  No.
Toggle Summary08/28/13 BioLineRx to Present at 15th International Celiac Disease Symposium
JERUSALEM , Aug. 28, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its abstract entitled "BL-7010: Non-Absorbable Polymeric Sequestering Agent for Celiac Disease" was accepted for an oral presentation at the 15th
Toggle Summary08/27/13 BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
JERUSALEM , Aug. 27, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its Chief Financial and Operating Officer, Philip Serlin , will be presenting at the 2013 Stifel
Toggle Summary08/19/13 BioLineRx Appoints B. J. Bormann to Board of Directors
JERUSALEM , Aug. 19, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today the appointment of B. J. Bormann , Ph.D., to its Board of Directors. (Logo: http://photos.prnewswire.com/prnh/20130730/630769 ) Dr.
Toggle Summary08/06/13 BioLineRx Reports Second Quarter 2013 Results
JERUSALEM – August 6, 2013 - BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, today reported its results for the quarter ended June 30, 2013. Recent Highlights: BL-1040 (ventricular remodeling) – The PRESERVATION I clinical trial, a CE-Mark registration trial, is
Toggle Summary08/05/13 BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
- Results published in the British Journal of Hematology - - BL-8040, currently in Phase 2 study for AML, continues to show promising results in other hematological indications -   Jerusalem, August 5, 2013 - BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced
Toggle Summary07/30/13 BioLineRx to Report Second Quarter 2013 Results on August 6, 2013
Management to hold a conference call at 10:00 a.m. EDT JERUSALEM --(BUSINESS WIRE)--Jul. 30, 2013-- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE: BLRX ), a biopharmaceutical development company, announced today that it will release its unaudited financial results for the quarter ended June 30, 2013 on
Toggle Summary07/29/13 BioLineRx Announces CE-Mark Registration Trial Submission for Novel Treatment for Removal of Skin Lesions
- Study expected to begin in Q4 2013 - - Results expected in mid-2014 - JERUSALEM --(BUSINESS WIRE)--Jul. 29, 2013-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has filed the necessary regulatory submissions to commence a pivotal, CE-Mark
Toggle Summary07/02/13 BioLineRx to Present at 2013 Annual JMP Securities Healthcare Conference in New York
JERUSALEM --(BUSINESS WIRE)--Jul. 2, 2013-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its Chief Financial and Operating Officer, Philip Serlin , will be presenting at the 2013
Toggle Summary06/10/13 BioLineRx Enters into Collaboration to Develop and Commercialize Hepatitis C Drug with CTTQ, Leading Chinese Pharma Company for Liver Disease Therapeutics
- BL-8030 is a pre-clinical, second-generation NS3 protease inhibitor - - CTTQ receives development and commercialization rights in China and Hong Kong - JERUSALEM --(BUSINESS WIRE)--Jun. 10, 2013-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that
Toggle Summary06/06/13 BioLineRx Enrolls First Patient in Phase 2 Clinical Trial for BL-8040, for Treatment of Leukemia
- Partial results expected in Q4 2013 – JERUSALEM --(BUSINESS WIRE)--Jun. 6, 2013-- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today enrollment of the first patient in a Phase 2 trial for BL-8040, for the treatment of acute myeloid leukemia (AML).
Toggle Summary05/17/13 BioLineRx Enters into “At-The-Market” Offering Agreement with Stifel, Nicolaus & Company
JERUSALEM --(BUSINESS WIRE)--May. 17, 2013-- BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a biopharmaceutical development company, announced today that it has entered into an at-the-market (ATM) sales agency agreement with Stifel. Pursuant to this agreement, the Company may from time to time, in its
Toggle Summary05/09/13 BioLineRx to Present at the Oppenheimer 14th Annual Israeli Conference on May 12th
JERUSALEM --(BUSINESS WIRE)--May. 9, 2013-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its Chief Financial and Operating Officer, Philip Serlin , will present at the
Toggle Summary05/07/13 BioLineRx Reports First Quarter 2013 Results
JERUSALEM --(BUSINESS WIRE)--May. 7, 2013-- BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a biopharmaceutical development company, today reported its results for the quarter ended March 31, 2013 . Recent Highlights: •   BL-7040 (IBD) – Received positive results from a Phase 2 proof-of-concept study to
Toggle Summary05/02/13 BioLineRx's BL-7010, for the Treatment of Celiac, to be Presented at Two Leading Conferences
JERUSALEM --(BUSINESS WIRE)--May. 2, 2013-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that the Company was invited to deliver an oral presentation at the 2013 National Education Conference & Gluten-Free Expo , the Celiac Disease
Toggle Summary04/30/13 BioLineRx to Report First Quarter 2013 Results on May 7, 2013
Management to Hold Conference Call at 10:00 A.M. EST JERUSALEM --(BUSINESS WIRE)--Apr. 30, 2013-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it will release its unaudited financial results for the quarter ended March 31, 2013 on
Toggle Summary04/29/13 BioLineRx Enrolls First Patient in Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
- Interim results are expected by the end of 2013 - JERUSALEM --(BUSINESS WIRE)--Apr. 29, 2013-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today enrollment of the first patient in a Phase I/II trial for BL-8020, an orally available, interferon-free
Toggle Summary04/18/13 BioLineRx to Present at the 12th Annual Needham Healthcare Conference in New York on April 30, 2013
JERUSALEM --(BUSINESS WIRE)--Apr. 18, 2013-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its Chief Financial and Operating Officer, Philip Serlin , will be presenting at the 12 th
Toggle Summary04/17/13 BioLineRx Announces Positive Phase II Results for BL-7040, an Orally Available Treatment for Inflammatory Bowel Disease
- BL-7040 met the primary efficacy endpoint of the study - - BL-7040 was also shown to be safe and well tolerated - JERUSALEM --(BUSINESS WIRE)--Apr. 17, 2013-- BioLineRx (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today positive Phase IIa results for BL-7040, an
Toggle Summary04/10/13 BioLineRx Receives Regulatory Approval to Commence Phase II Clinical Trial for BL-8040, for Treatment of Leukemia
Partial results expected in Q4 2013 Final results expected in H2 2014 JERUSALEM --(BUSINESS WIRE)--Apr. 10, 2013-- BioLineRx (NASDAQ:BLRX)(TASE:BLRX), a biopharmaceutical development company, announced today that it has received all necessary regulatory approvals in the US to commence a Phase IIa
Toggle Summary03/20/13 BioLineRx Announces Results from Interim Analysis of Phase II/III CLARITY Trial of BL-1020 for Schizophrenia
Management call scheduled for Wednesday, March 20 th , at 11:00 a.m. EDT JERUSALEM --(BUSINESS WIRE)--Mar. 20, 2013-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today announced that results from a pre-planned interim analysis of the Phase II/III CLARITY trial of
Toggle Summary03/13/13 BioLineRx Receives Approval from French Regulatory Authorities to Commence a Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
- Interim results are expected by the end of 2013 - JERUSALEM --(BUSINESS WIRE)--Mar. 13, 2013-- BioLineRx (NASDAQ:BLRX)(TASE:BLRX), a biopharmaceutical development company, announced today that it has received approval from the French regulatory authorities to commence a Phase I/II trial for
Toggle Summary03/12/13 BioLineRx Reports Year End 2012 Financial Results
Download PDF JERUSALEM--(BUSINESS WIRE)--Mar. 12, 2013-- BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a biopharmaceutical development company, today reported its results for the year ended December 31, 2012 . “BioLineRx is rapidly approaching a significant landmark in the evolution of the Company,”
Toggle Summary02/28/13 BioLineRx's EDP-14, for Treatment of Severe and Persistent Asthma, to Enter the Company's Main Therapeutic Pipeline as BL-9010
Preclinical data shows that EDP-14 significantly blocks allergic responses JERUSALEM --(BUSINESS WIRE)--Feb. 28, 2013-- BioLineRx (NASDAQ: BLRX)(TASE: BLRX), a biopharmaceutical development company, announced today that following promising pre-clinical data, EDP-14, for the treatment of severe and
Toggle Summary02/26/13 BioLineRx to Report Fourth Quarter and Year End 2012 Results on March 12, 2013
– Management to hold conference call at 10:00 a.m. EST– JERUSALEM --(BUSINESS WIRE)--Feb. 26, 2013-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it will release its financial results for the quarter and year ended December 31, 2012 on
Toggle Summary02/13/13 BioLineRx Announces Closing of $8 Million Offering of American Depositary Shares
JERUSALEM --(BUSINESS WIRE)--Feb. 13, 2013-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has closed its previously announced direct placement to leading healthcare investor, OrbiMed Israel Partners Limited Partnership , an affiliate
Toggle Summary02/06/13 BioLineRx Announces Offering of American Depositary Shares
JERUSALEM --(BUSINESS WIRE)--Feb. 6, 2013-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has entered into a definitive agreement with leading healthcare investor OrbiMed Israel Partners Limited Partnership , an affiliate of OrbiMed
Toggle Summary02/04/13 BioLineRx Provides Clarification Regarding Interim Analysis of CLARITY Trial for BL-1020
JERUSALEM --(BUSINESS WIRE)--Feb. 4, 2013-- BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a biopharmaceutical development company, notes that, as previously disclosed, results from the interim analysis of the Phase II/III CLARITY clinical trial of BL-1020, a first in class, orally available,
Toggle Summary01/31/13 BioLineRx to Present at the 2013 BIO CEO & Investor Conference in New York on February 12th
JERUSALEM --(BUSINESS WIRE)--Jan. 31, 2013-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its Chief Financial and Operating Officer, Philip Serlin , will be presenting at the 2013 BIO
Toggle Summary01/07/13 BioLineRx to Announce Interim Results of Phase II/III Trial for Schizophrenia Drug During Week of March 18, 2013
- Cognition impairment is primary endpoint of CLARITY phase II/III trial - - Dr. Savitsky: "BL-1020's interim results mark an important landmark in the development of our lead product and the Company as a whole" - JERUSALEM --(BUSINESS WIRE)--Jan. 7, 2013-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a
Toggle Summary11/30/12 BioLineRx to Present at the 2012 Fifth Annual LD MICRO Conference in Los Angeles on December 5th
JERUSALEM --(BUSINESS WIRE)--Nov. 30, 2012-- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE:BLRX), a biopharmaceutical development company, today announced that its management team will be presenting at the 2012 Fifth Annual LD MICRO Conference at the Luxe Sunset Bel Air Hotel in Los Angeles .
Toggle Summary11/14/12 BioLineRx Reports Third Quarter 2012 Financial Results
Download PDF Jerusalem, Israel – November 14, 2012 – BioLineRx Ltd. (NASDAQ: BLRX ; TASE: BLRX), a biopharmaceutical development company, today reported its results for the third quarter ending September 30, 2012. Highlights of the Third Quarter of 2012 and Recent Developments: BL-1020
Toggle Summary11/12/12 BioLineRx to Hold Analyst and Investor Day in New York on December 4, 2012
JERUSALEM --(BUSINESS WIRE)--Nov. 12, 2012-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced that it will host an Analyst & Investor Day on Tuesday, December 4, 2012 in New York City beginning at 8:00 am EST .
Toggle Summary11/07/12 BioLineRx Announces BL-8040, for the Treatment of Leukemia and Other Types of Hematological Cancer, to be Presented at 2012 ASH Annual Meeting
JERUSALEM --(BUSINESS WIRE)--Nov. 7, 2012-- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE: BLRX ), a biopharmaceutical development company, announced today that in vivo and in vitro data demonstrating the efficacy of BL-8040 in treating chronic myeloid leukemia (CML) has been accepted for presentation at
Toggle Summary11/05/12 BioLineRx to Report Third Quarter 2012 Results on November 14, 2012
Management to hold conference call at 9:00 a.m. EST JERUSALEM --(BUSINESS WIRE)--Nov. 5, 2012-- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE: BLRX ), a biopharmaceutical development company, announced today that it will release its unaudited financial results for the quarter ended September 30, 2012 on
Toggle Summary10/24/12 BioLineRx to Conduct Interim Analysis of Phase II/III CLARITY Clinical Trial of BL-1020 for Treatment of Schizophrenia
– Results of interim analysis expected in Q1 2013 – JERUSALEM --(BUSINESS WIRE)--Oct. 24, 2012-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it intends to conduct an interim analysis of the Phase II/III CLARITY trial of BL-1020, a first in
Toggle Summary10/16/12 BioLineRx Announces Successful Completion of Pre-Clinical Development for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
- Phase I/II clinical study expected to commence in Q1 2013 - JERUSALEM --(BUSINESS WIRE)--Oct. 16, 2012-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has successfully completed the pre-clinical development of BL-8020, an orally available,
Toggle Summary10/09/12 BioLineRx Announces New Analysis of EAGLE Phase IIb Study Showing a Significantly Greater Beneficial Effect of BL-1020 on Cognitive Function in Schizophrenia Patients
–BL-1020 is currently undergoing the CLARITY Phase II/III clinical trial with results expected in H2 2013– JERUSALEM --(BUSINESS WIRE)--Oct. 9, 2012-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that a recent analysis of the results from the Phase
Toggle Summary09/27/12 BioLineRx Enters into Share Purchase Agreement with Lincoln Park Capital
JERUSALEM --(BUSINESS WIRE)--Sep. 27, 2012-- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE: BLRX ), a biopharmaceutical drug development company, announced today that it has signed a purchase agreement for the sale, from time to time, of up to $15 million of its American Depositary Shares (“ADSs”) with
Toggle Summary09/27/12 BioLineRx Announces Publication of EAGLE Study Results Demonstrating BL-1020's Efficacy in Improving Cognitive Function in Schizophrenia Patients
– Results of Phase IIb clinical trial from September 2009 now published in the Journal of Clinical Psychiatry – – BL-1020 is currently undergoing Phase II/III CLARITY clinical trial with results expected in H2 2013 – JERUSALEM --(BUSINESS WIRE)--Sep. 27, 2012-- BioLineRx (NASDAQ: BLRX) (TASE:
Toggle Summary09/24/12 BioLineRx Receives Notice of Allowance from USPTO for New Patent on BL-1020, Extending Patent Protection Until 2031
Untitled Document - New patent provides at least nine years of additional protection over patents previously granted - Jerusalem, Israel – September 24, 2012 – BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that a Notice of Allowance has been received
Toggle Summary09/24/12 BioLineRx Receives Notice of Allowance from USPTO for New Patent on BL-1020, Extending Patent Protection Until 2031
- New patent provides at least nine years of additional protection over patents previously granted - JERUSALEM --(BUSINESS WIRE)--Sep. 24, 2012-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that a Notice of Allowance has been received from the
Toggle Summary09/10/12 BioLineRx Announces Pre-clinical Results Demonstrating the Safety of BL-7010, an Oral Treatment for Celiac Disease and Gluten Sensitivity
- The new safety data, as well as pre-clinical efficacy results, presented at the Better Life for Coeliacs 2012 Conference -   Jerusalem, Israel – September 10, 2012 – BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that BL-7010, an orally available
Toggle Summary09/04/12 BioLineRx In-Licenses a Novel, Phase II Ready Drug for the Treatment of Leukemia and Other Hematological Cancers
- Phase II clinical trials are expected to commence in H1 2013 -   Jerusalem, Israel, September 4, 2012 --- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE: BLRX ), a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine
Toggle Summary08/15/12 BioLineRx Reports Second Quarter 2012 Results
Toggle Summary08/02/12 BioLineRx to Report Second Quarter 2012 Results on August 15, 2012
Jerusalem, Israel, August 2, 2012 --- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE: BLRX ), a biopharmaceutical development company, announced today that it will release its unaudited financial results for the three-months ended June 30, 2012 on Wednesday, August 15, 2012, before the U.S. markets open.
Toggle Summary07/09/12 BioLineRx Receives Notice of Intention to Grant Additional European Patent Covering BL-1020, for the Treatment of Schizophrenia
Jerusalem, July 9, 2012 - BioLineRx (NASDAQ:BLRX; TASE:BLRX), a biopharmaceutical development company, announced today that it has received from the European Patent Office a notice of intention to grant a European patent claiming the salt of BL-1020, a first-in-class orally available treatment for
Toggle Summary06/13/12 Research Underlying BioLineRx's EDP 10, for Treatment of Type 1 Diabetes, Wins Hebrew University's Kaye Award
For Hebrew convenience translatioin, please click below Hebrew version Jerusalem, Israel – June 13, 2012 – BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that research underlying its EDP 10 project for the treatment of type 1 diabetes won the Hebrew
Toggle Summary06/05/12 BioLineRx Announces Receipt of Two Notices of Allowance from USPTO for Patents Covering BL-1021, for Treatment of Neuropathic Pain
For Hebrew convenience translation, please click link below: Hebrew version Jerusalem, Israel - June 5, 2012 - BioLineRx (NASDAQ:BLRX; TASE:BLRX), a biopharmaceutical development company, announced today that two Notices of Allowance have been issued by the United States Patent and Trademark Office
Toggle Summary05/15/12 BioLineRx Reports First Quarter 2012 Results
For Hebrew convenience translation please click link below Hebrew version Jerusalem, May 15, 2012 --BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today reported its results for the quarter ended March 31, 2012. Highlights for the First Quarter of 2012:
Toggle Summary05/08/12 BioLineRx to Report First Quarter 2012 Results on May 15, 2012
For Hebrew convenience translation, please click link below: Hebrew version Jerusalem, Israel, May 8, 2012 --- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it will release its unaudited financial results for the three-months ended March
Toggle Summary04/25/12 BioLineRx Announces Extension of Patent for BCM (BL-1040) by USPTO
For Hebrew convenience translation please click on link below: Hebrew version Jerusalem, Israel – April 25, 2012 - BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that an Issue Notification has been received from the United States Patent and Trademark
Toggle Summary04/23/12 BioLineRx Launches Free Investor Relations App for iPhone
JERUSALEM, April 23, 2012 -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX.TA), a biopharmaceutical development company, announced the release today of its investor relations app for iPhone, now available for free at the Apple App store on the iPhone or at http://bit.ly/I6oKhw .
Toggle Summary03/28/12 BioLineRx to Present at the 2012 Annual Needham Healthcare Conference in New York on April 3rd
JERUSALEM, March 28, 2012 -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX.TA), a biopharmaceutical development company, today announced that its Chief Financial and Operating Officer, Philip Serlin, and its Vice President of Research and Development, Leah Klapper, Ph.D., will be presenting at the 2012
Toggle Summary03/22/12 BioLineRx Reports Fourth Quarter and Calendar 2011 Results
Jerusalem , March 22, 2012 - BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today reported its results for the fourth quarter and year ended December 31, 2011. Kinneret Savitsky, Ph.D., CEO of BioLineRx, remarked, “2011 was a very significant year for BioLineRx
Toggle Summary03/07/12 BioLineRx Announces Grant of European Patent Covering BL-1020, an Orally Available Treatment for Schizophrenia
For Hebrew convenience translation please click on the link below Hebrew version Jerusalem, March 7, 2012 - BioLineRx (NASDAQ:BLRX; TASE:BLRX), a biopharmaceutical development company, announced today that a European patent has been granted claiming BL-1020's composition and its use for the
Toggle Summary03/07/12 BioLineRx to Present at the 2012 Annual Roth Growth Conference in Orange County, California on March 14th
JERUSALEM, March 7, 2012 -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, today announced that its Chief Executive Officer, Kinneret Savitsky, and its Vice President of Business Development, David Malek, will be presenting at the 2012 Annual Roth Growth
Toggle Summary03/05/12 BioLineRx Receives Approval for Commencing Phase II Clinical Trial of BL-7040, an Orally Available Treatment for Inflammatory Bowel Disease
BioLineRx Receives Approval for Commencing Phase II Clinical Trial of BL-7040, an Orally Available Treatment for Inflammatory Bowel Disease For Hebrew convenience translation please click link below Hebrew version Jerusalem, March 5, 2012 - BioLineRx (NASDAQ:BLRX; TASE:BLRX) a biopharmaceutical
Toggle Summary02/29/12 BioLineRx Announces Receipt of Notice of Allowance from USPTO for Patent Covering BCM (BL-1040), a Novel Medical Device for Prevention of Cardiac Remodeling Following Acute Myocardial Infarction
For Hebrew conveneience translation please click link below: Hebrew version Jerusalem, Israel - February 29, 2012 - BioLineRx (NASDAQ:BLRX; TASE:BLRX), a biopharmaceutical development company, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark
Toggle Summary02/28/12 BioLineRx Ltd. Announces Closing of $15 Million Private Placement to Institutional Investors
JERUSALEM, February 28, 2012 -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX), announced today that it has closed its previously announced $15 million private placement to healthcare-focused U.S. institutional investors. As a result, the Company sold approximately 5.25 million American Depositary Shares
Toggle Summary02/21/12 BioLineRx Announces Publication of Pre-clinical Results Demonstrating Efficacy of BL-7010, an Oral Treatment for Celiac Disease and Gluten Sensitivity
For Hebrew convenience translation please click below Hebrew Version Jerusalem, Israel – February 21, 2012 – BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for
Toggle Summary02/16/12 BioLineRx to place $15 million in securities with Institutional Investors
For Hebrew convenience translation please click link below: Hebrew Version Jerusalem, Israel - February 16, 2012 – BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) (the "Company”), a biopharmaceutical development company, announced today it has entered into definitive agreements with healthcare-focused
Toggle Summary02/07/12 BioLineRx to present at the BIO CEO & Invvestor Conference
Jerusalem, Israel, February 7, 2012 - BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 2012 BIO CEO &
Toggle Summary02/06/12 BioLineRx In-Licenses Second Oral Hepatitis C Treatment
For Hebrew convenience translation please press link below Hebrew version   Jerusalem, Israel – February 6, 2012 – BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to
Toggle Summary01/24/12 BioLineRx Signs Exclusive License Agreement for BL-8020, an Oral Treatment for Hepatitis C
For Hebrew convenience translation please click on link Hebrew Translation Jerusalem, Israel – January 24, 2012 – BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience, a French company
Toggle Summary01/03/12 BioLineRx Announces Initiation of CE Mark Registration Trial for BCM (BL-1040), a Novel Medical Device for Prevention of Cardiac Remodeling Following Acute Myocardial Infarction
For Hebrew convenience translation please click link below : Hebrew version Jerusalem, January 3, 2011 - BioLineRx (NASDAQ:BLRX; TASE:BLRX), a biopharmaceutical development company, announced today the commencement of the PRESERVATION I clinical trial, a CE Mark registration trial of BCM (BL-1040),
Toggle Summary12/13/11 BioLineRx to Develop and Commercialize Novel Peptide Drug Candidates Discovered by Compugen
For Hebrew convenience translation please click link below: Hebrew Version Jerusalem and Tel Aviv, Israel - December 13, 2011 – BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, and Compugen Ltd. (NASDAQ: CGEN), a drug discovery company, announced today that they have
Toggle Summary12/06/11 BioLineRx Announces Positive Final Results from Phase Ia Clinical Trial of BL-1021 for Neuropathic Pain
For Hebrew convenience translation please click link below: Hebrew version Jerusalem, December 6, 2011 - BioLineRx (NASDAQ:BLRX) (TASE:BLRX) announced today the final results of the Phase Ia study of BL-1021, an orally available small molecule for neuropathic pain.
Toggle Summary11/29/11 BioLineRx Reports Third Quarter 2011 Financial Results
Toggle Summary11/22/11 BioLineRx Announces Receipt of Approval in India to Commence Phase II/III CLARITY Clinical Trial of BL-1020 for Treatment of Schizophrenia
For Hebrew convenience translation please click on the link below Hebrew Version Jerusalem, November 22, 2011 - BioLineRx (NASDAQ:BLRX; TASE:BLRX), a biopharmaceutical development company, announced today that it has received approval from the Indian regulatory authorities and the Indian local
Toggle Summary09/27/11 BioLineRx to Present Data from the Successfully Completed Phase IIb trial of BL-1020 at European Conference on Schizophrenia Research
For Hebrew version please click below: Hebrew version Jerusalem, Israel, Sep. 27, 2011 – BioLineRx (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, today announced that data from the successfully completed Phase IIb EAGLE  study of BL-1020, a first in class GABA-enhanced
Toggle Summary09/16/11 BioLineRx to Present at Annual UBS Global Life Sciences Conference in New York on September 21st
Jerusalem, September 16, 2011 - BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today announced that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 2011 UBS Global Life
Toggle Summary09/15/11 BioLineRx Announces European Confirmation of Medical Device Regulatory Pathway for BL-5010, for Non-surgical Removal of Skin Lesions
For Hebrew version please click link below Hebrew Version Jerusalem , Israel, September 15, 2011 - BioLineRx (NASDAQ: BLRX) (TASE: BLRX),  a biopharmaceutical development company, announced today that BL-5010, for the non-surgical removal of benign skin lesions, has received European confirmation
Toggle Summary09/13/11 BioLineRx Announces Positive Preliminary Results from Phase I Clinical Trial of BL-1021 for Neuropathic Pain
For Hebrew version please click on the link below: Hebrew Version Jerusalem, September 13, 2011 - BioLineRx (NASDAQ: BLRX) (TASE: BLRX) announced today the last visit of the last subject and preliminary results of the Phase Ia study of BL-1021, an orally available small molecule for neuropathic
Toggle Summary09/08/11 BioLineRx to Present at Annual Rodman and Renshaw Conference in New York on September 13th
Jerusalem, September 8, 2011 – BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today announced that its Chief Executive Officer, Kinneret Savitsky, and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 2011 Rodman and Renshaw
Toggle Summary09/07/11 BioLineRx In-Licenses BL-7050, a Novel Orally Available Molecule for the Treatment of Neuropathic and Inflammatory Pain
For Hebrew version please click on the link below: Hebrew Version Jerusalem, September 7, 2011 - BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the
Toggle Summary08/23/11 BioLineRx Reports Second Quarter 2011 Financial Results
Jerusalem , August 23, 2011 - BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today reported its results for the second quarter ending June 30, 2011. “During the second quarter we continued developing, advancing and enriching our pipeline, while focusing on
Toggle Summary07/25/11 BioLineRx ADRs Begin Trading on NASDAQ
Jerusalem, July 25, 2011 - BioLineRx (TASE: BLRX) (NASDAQ: BLRX), a biopharmaceutical development company, today announced that it has listed and begun trading American Depositary Receipts (ADRs) through BNY Mellon. Each BioLineRx ADR represents 10 ordinary shares and trades on the NASDAQ Capital
Toggle Summary07/05/11 BioLineRx Announces Plans to Launch ADR Program on NASDAQ
Jerusalem, July 5, 2011 - BioLineRx (TASE:BLRX), a biopharmaceutical drug development company, today announced that it plans to list its shares through American Depositary Receipts (ADRs), to be traded on the NASDAQ under ticker "BLRX.” The Bank of New York Mellon has been appointed as the
Toggle Summary07/05/11 BioLineRx Announces First Subject Enrolled in Phase I Clinical Trial of BL-1021 for Neuropathic Pain
Jerusalem, July 5, 2011 - BioLineRx (TASE:BLRX) announced today the enrollment of the first subject in a Phase I study of BL-1021, an orally available small molecule for treating neuropathic pain. This clinical trial will be a first-in-human, single-site, double-blind, placebo controlled study to
Toggle Summary06/28/11 BioLineRx Announces First Patient Enrolled in Phase II/III CLARITY Clinical Trial for BL-1020, a First in Class GABA-Enhanced AntipsychoticTreatment for Schizophrenia
Jerusalem, June 28, 2011 - BioLineRx (TASE:BLRX), a biopharmaceutical development company, announced today the enrollment of the first patient in the Phase II/III CLARITY clinical trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.
Toggle Summary06/27/11 BioLineRx Signs Exclusive License Agreement with Yissum for Oral Phase II Ready Treatment BL-7040 for Inflammatory Bowel Disease
Jerusalem, June 27, 2011 - BioLineRx (TASE:BLRX), a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for
Toggle Summary05/17/11 BioLineRx Acquires Exclusive License Rights From Algen for Cancer Therapeutic BL-7030
Jerusalem, May 17, 2011 . BioLineRx (TASE:BLRX) announced today that it has acquired the rights to compound BL-7030, a novel molecule for targeted cancer therapy, from Algen, which received exclusive rights from Yissum, the Hebrew University of Jerusalem.  BL-7030 is a vector targeted to epidermal
Toggle Summary05/11/11 BioLineRx Reacquires Rights to leading Schizophrenia Drug Candidate BL-1020
Jerusalem, Israel, May 11, 2011 – BioLineRx Ltd. (TASE: BLRX), a biopharmaceutical development company dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies, announced today the signing of an agreement with Cypress Bioscience
Toggle Summary04/04/11 BioLineRx Receives Notice of Allowance from USPTO for Patent Covering BL-1020 Drug for Treatment of Schizophrenia
Jerusalem, April 4, 2011 . BioLineRx (TASE:BLRX) announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application covering the BL-1020 drug and its use for the treatment of schizophrenia.
Toggle Summary03/28/11 BioLineRx: Financial Results for 2010
Jerusalem, March 28, 2011 . BioLineRx (TASE: BLRX) announces its financial results for 2010. • 2010 revenue increased to NIS 113.2 million from NIS 63.9 million in 2009 • Cash and short term investments at December 31 2010 were NIS 139.8 million Dr. Kinneret Savitsky, BioLine's CEO , stated, "We
Toggle Summary02/27/11 First Pivotal Trial for BL-1040, Medical Device for Patients Following Acute Myocardial Infarction, Anticipated to Commence in H2 2011
BioLineRx (TASE:BLRX) announced today that the first pivotal trial for BL-1040*, a novel medical device intended for patients following acute myocardial infarction (AMI), is anticipated to commence in the second half of 2011. Ikaria Inc., which acquired the license for continuation of development
Toggle Summary01/23/11 BioLineRx Announces Cypress Bioscience’s and Royalty Pharma’s Commitment to the Development of the BL-1020 (CYP-1020) Program
Jerusalem, January 23, 2011 . BioLineRx (TASE:BLRX) today announced that it has been advised by Royalty Pharma, the new parent company of Cypress Bioscience Inc., that it is committed to enhance the value of Cypress’ pipeline assets, which include BioLineRx’s BL-1020 (CYP-1020) compound, a novel
Toggle Summary01/04/11 BioLineRx and Israeli Office of Chief Scientist (OCS) renew franchise for BioLine Innovations Jerusalem, the sole Israeli Biotech incubator approved by OCS
Jerusalem, January 4, 2011 . BioLineRx (TASE:BLRX) announces that the Office of the Chief Scientist at the Israeli Ministry of Industry, Trade and Labor (OCS) has renewed BioLineRx's franchise for the biotechnology incubator, BioLine Innovations Jerusalem (BIJ), for an additional two years.
Toggle Summary12/28/10 Positive Results from Phase I/II Trial of BL-5010 for Non-Surgical Removal of Skin lesions
Jerusalem, December 28, 2010. BioLineRx (TASE:BLRX) announces receipt of positive results from the Phase I/II clinical trial of BL-5010, a novel formulation for the non-surgical removal of skin lesions.   The recently completed open-label, single-arm trial was conducted in 60 patients with
Toggle Summary12/06/10 BioLineRx participated in Investor Conference in New York for Israeli Biomed companies co-sponsored by NASDAQ and TASE
Opening bell ceremony at NASDAQ with participants from NASDAQ-TASE Biomed Investors Conference. VP Business Development of BioLineRx, Nir Gamliel, is  fourth on the right.
Toggle Summary11/29/10 BioLineRx to participate in Investor Conference in New York co-sponsored by NASDAQ and TASE
Jerusalem, Israel, November 29, 2010 . BioLineRx (BLRX: TASE) is pleased to announce that it will participate in an investor conference highlighting the life-sciences industry on December 6, 2010, co-sponsored by NASDAQ and the Tel-Aviv Stock Exchange (TASE).
Toggle Summary11/24/10 BioLineRx Reports Results for Q3 2010 : Revenues of NIS 113 Million and Net Profit of NIS 73.1 Million
Jerusalem, November 24, 2010 - BioLineRx (BLRX:TASE) reports its operating results for the quarter and nine months ended September 30, 2010. Highlights: • Revenues in Q3 amounted to NIS 113 million, resulting from the commercialization of BL-1020 to Cypress Bioscience Inc.
Toggle Summary10/27/10 Distinguished poster award for research quality received at ISCTM
Jerusalem, Israel, October 27, 2010 . BioLineRx is pleased to announce receipt of a distinguished poster award for the clinical trial of BL-1020, a novel molecule for the treatment of schizophrenia, at the 6th International Society for CNS Clinical Trials and Methodology (ISCTM) Conference,
Toggle Summary08/30/10 BioLineRx presents data on BL-1021, a New Chemical Entity for treatment of neuropathic pain, at 13th World Congress on Pain, Montreal, Canada
Jerusalem, Israel, August 30, 2010 . BioLineRx is pleased to announce that data on BL-1021, a new chemical entity (NCE) for treatment of neuropathic pain, will be presented at 13th World Congress on Pain, Montreal Canada. This Congress is the biennial meeting of the International Association for
Toggle Summary08/24/10 Early Development Program (EDP) Yields Results: EDP-01, an Innovative Molecule for Type II Diabetes, Enters the Company's Main Product Pipeline
EDP-01, an innovative compound for treating type II diabetes, has successfully completed BioLineRx's Early Development Program (EDP) and will enter the Company's main product pipeline. This is a significant milestone for BioLineRx, as EDP-01 is the first graduate of the EDP program to enter its
Toggle Summary08/11/10 Deal with Cypress Bioscience Inc. has been approved by Office of the Chief Scientist
Jerusalem, 11 August, 2010 - BioLineRx (TASE: BLRX) is pleased to announce that it has received approval from the Israeli Office of the Chief Scientist of the Ministry of Industry, Trade and Labor (“OCS”) for the out-licensing agreement with Cypress Bioscience, Inc. (NASDAQ: CYPB).
Toggle Summary07/11/10 BioLineRX is planning a listing on the NASDAQ
Jerusalem, July 11, 2010 .  The Company hereby announces that, on July 11, 2010, the Company’s Board of Directors formally approved the process of registration with the U.S. Securities and Exchange Commission of an offering of the Company’s shares and a simultaneous listing of its securities on the
Toggle Summary06/21/10 BioLineRx signs second out-licensing agreement within one year
Jerusalem, 20 June, 2010 - BioLineRx (TASE: BLRX) has signed an out-licensing agreement for BL-1020, a novel drug for schizophrenia, with Cypress Bioscience, Inc., a US-based pharmaceutical company (NASDAQ: CYPB). Closing of the transaction is subject to the approval of the Israeli Office of the
Toggle Summary05/16/10 BioLineRx receives GLP accreditation for Analytical Laboratories
The Israel Laboratory Accreditation Authority (ISRAC) has granted BioLineRx's analytical laboratories Good Laboratory Practices (GLP)  accreditation as of  March 4, 2010 . From this date, BioLineRx's analytical laboratories have been added to the ISRAC test facilities list and are officially
Toggle Summary04/28/10 BioLineRx Announces Ikaria's $10 million Payment on Successful Completion of BL-1040's Phase I/II
BioLineRx Ltd . (the "Company") is pleased to announce that Ikaria Holdings Inc. has made a $10 million milestone payment, according to the terms of the licensing agreement between the parties, following successful completion of the phase I/II clinical trial assessing the safety and feasibility of
Toggle Summary04/13/10 BioLineRx's Dr. Geffen will present results from Phase 2b EAGLE trial at Schizophrenia International Research Society (SIRS) Conference , Florence, Italy
On Thursday April 15,  Yona Geffen, PhD, from BioLineRX will be presenting "A double-blind placebo control study evaluating the efficacy and safety of BL-1020 , a GABA enhanced antipsychotic for the treatment of schizophrenia" at  the SIRS Conference, "Cognition in Schizophrenia" Session.
Toggle Summary03/07/10 Final Assessment of the Independent Safety Monitoring Board (ISMB) regarding the BL-1040 Phase I/II Clinical Trial Results
BioLineRx Ltd. (“the Company”) is pleased to announce that on March 4, 2010, it received the final assessment of the ISMB regarding the Phase I/II clinical trial for BL-1040, a medical device indicated for the treatment of patients who have experienced a heart attack.
Toggle Summary01/17/10 BioLineRx Announces Positive Results from Its Phase 2b EAGLE Extension Trial Assessing the Safety and Efficacy of BL-1020
Jerusalem, Israel, January 17th, 2010: Following our previous press releases (published September 14th and 23rd, 2009) announcing that BL-1020 has successfully met its primary and secondary efficacy endpoints, as well as significantly improved cognition in the 6-week phase 2b EAGLE (Effective
Toggle Summary10/18/09 BioLineRx’s Early Development Program Awarded a prestigious R&D Grant from the Canada-Israel Research & Development Foundation (CIIRDF)
Jerusalem, Israel, October 15, 2009 - BioLineRx Ltd. (TASE: BLRX), a clinical stage drug development company, today announced that its Early Development Program (EDP) has been awarded a prestigious R&D grant from the Canada-Israel Research & Development Foundation (CIIRDF).
Toggle Summary09/24/09 EAGLE Trial Signals Breakthrough in the Treatment of Schizophrenia
Jerusalem, Israel: Following our previous press release (published September 14th, 2009) announcing that BL-1020 has successfully met its primary and secondary efficacy endpoints from the phase 2b EAGLE (Effective Anti-psychosis via GABA Level Enhancement) trial, we are pleased to report positive
Toggle Summary09/14/09 BioLineRx Announces Positive Topline Results for BL-1020, a First in Class GABA Enhanced Antipsychotic for the Treatment of Schizophrenia
BL-1020 meets primary and secondary efficacy endpoints from the phase 2b EAGLE trial Jerusalem, Israel, September 14th, 2009- BioLineRx announced today top line results from its phase 2b EAGLE (Effective Antipsychosis via GABA Level Enhancement) study assessing the efficacy, safety and tolerability
Toggle Summary07/06/09 Ikaria® to In-License BioLineRx’s BL-1040
Clinton, NJ and Jerusalem, Israel, July 6, 2009 – Ikaria Holdings, Inc. and BioLineRx Ltd. (TASE: BLRX) today announced that Ikaria has entered into an agreement to obtain a worldwide exclusive license to BioLineRx’s BL-1040, a potential breakthrough treatment for preventing pathological cardiac
Toggle Summary06/21/09 BioLineRx Announces New Results Confirming the Mode of Action of Its Anti-Psychotic Drug- BL-1020
BioLineRx’s CEO Dr. Morris Laster: “These results are extremely important for the confirmation of the mode of action of BL-1020 in reducing EPS and improving cognition” Jerusalem, Israel, June 21st, 2009- BioLineRx, a drug development company with products in advanced clinical and pre-clinical
Toggle Summary06/21/09 BioLineRx Initiates Phase I/II Trial of BL-5010, a Novel Formulation for the Non Surgical Removal of Skin Lesions
BioLineRx’s CEO Dr. Morris Laster: “BL-5010 is an exciting product in development that may offer a fast, safe and painless way to eliminate skin lesions.” BioLineRx, a drug development company with products in advanced clinical and pre-clinical testing, today announced the initiation of a Phase
Toggle Summary06/01/09 BioLineRx Announces Positive Preliminary Results from the Phase I/II Trial of BL-1040, the First Injectable Device Addressing Pathological Cardiac Remodeling
• Fifteen Patients Successfully Treated With BL-1040 With No Complications; • Five Patients Completed Six Months Follow up Period with prevention of LV remodeling Jerusalem, ISRAEL, June, 2009 - BioLineRx Ltd. (TASE: BLRX), a clinical stage drug development company, today announced positive
Toggle Summary05/18/09 BioLineRx presents data at SOBP demonstrating the potential benefit of BL-1020 in improving cognition
BioLineRx Ltd. (TASE: BLRX) announced that data from preclinical behavioral models of BL-1020, a GABA-enhanced antipsychotic for the treatment of schizophrenia, will be presented today at the Society of Biological Psychiatry (SOBP) 64rd Annual Scientific Convention & Meeting held in Vancouver,
Toggle Summary04/30/09 BioLineRx completes recruitment for its BL-1020 Phase IIb EAGLE study in schizophrenia. Results are expected in Q3 2009.
BioLineRx completed the enrolment of 360 schizophrenia patients for BL-1020 phase IIb trial. The company completed the recruitment phase two months ahead of schedule. BioLineRx started the phase IIb trial, aimed at evaluating the efficacy, tolerability and safety of BL-1020 in July 2008.
Toggle Summary01/12/09 BioLineRx Receives Approval to Complete Phase 1/2 Clinical Trials of BL-1040, a Breakthrough Treatment for Acute Myocardial Infarction
Five out of 30 patients already safely treated. Final results of trial expected in Q3 2009 Jerusalem, ISRAEL, January 12, 2009 - BioLineRx Ltd. (TASE: BLRX), a clinical stage drug development company, today announced that the Independent Safety Monitoring Board (ISMB) for the BL-1040 pilot study
Toggle Summary11/12/08 BioLineRx and Yissum Sign a Licensing Agreement for the Development of a Novel Compound for the Treatment of Inflammatory Bowel Disease
Jerusalem, Israel, November 12, 2008 – Yissum Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, and BioLineRx Ltd. (TASE: BLRX), a clinical stage drug development company, today announced that they have signed a worldwide exclusive license agreement for BioLineRx to
Toggle Summary07/16/08 BioLineRx's BL-1040 Named One of 10 Most Promising Cardiovascular Projects by Windhover
Jerusalem, Israel, July 16, 2008 – BioLineRx Ltd. (TASE: BLRX), a clinical stage drug development company, announced today that BL-1040, a novel myocardial implant for the treatment of acute myocardial infarction (MI), has been selected as one of the Top 10 most promising cardiovascular projects in